Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Retsevmo ® (selperkatinib)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
The recommended dose of selpercatinib in adult and adolescent patients 12 years of age or older is
160 mg orally twice daily for patients with an actual body weight ≥50 kg, and
120 mg orally twice daily for patients with an actual body weight <50 kg.1
Patients should take the doses at approximately the same time every day.1
If a patient vomits or misses a dose, the patient should be instructed to take the next dose at its scheduled time. An additional dose should not be taken.1
Selpercatinib capsules must be swallowed whole if possible. lf a patient cannot swallow the capsules, then alternative administration instructions must be followed to ensure the integrity of the selpercatinib dose.2
Selpercatinib may be taken with or without food unless coadministered with a PPI.1
Selpercatinib is taken orally twice daily until disease progression or unacceptable toxicity. Table 1 details the recommended dose of selpercatinib based on actual body weight.1
Table 1. Recommended Selpercatinib Dosage1,3
Patient Weighta |
Recommended Dosage |
<50 kg |
120 mg orally twice daily |
≥50 kg |
160 mg orally twice daily |
a Based on actual patient weight.
1. Retsevmo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3. Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2021 M01 04